Related Experiment Video
Updated: May 4, 2026

Controllable Ion Channel Expression through Inducible Transient Transfection
Published on: February 17, 2017
Understanding the cellular function of TRPV2 channel through generation of specific monoclonal antibodies
Matthew R Cohen1, Kevin W Huynh2, Daniel Cawley3
1Department of Physiology & Biophysics, School of Medicine, Case Western Reserve University, Cleveland, Ohio, United States of America ; Department of Pharmacology, School of Medicine, Case Western Reserve University, Cleveland, Ohio, United States of America.
Abstract:
Transient receptor potential vanilloid 2 (TRPV2) is a Ca(2+)-permeable nonselective cation channel proposed to play a critical role in a wide array of cellular processes. Although TRPV2 surface expression was originally determined to be sensitive to growth factor signaling, regulated trafficking of TRPV2 has remained controversial. TRPV2 has proven difficult to study due to the lack of specific pharmacological tools to modulate channel activity; therefore, most studies of the cellular function of TRPV2 rely on immuno-detection techniques. Polyclonal antibodies against TRPV2 have not been properly validated and characterized, which may contribute to conflicting results regarding its function in the cell. Here, we developed monoclonal antibodies using full-length TRPV2 as an antigen. Extensive characterization of these antibodies and comparison to commonly used commercially available TRPV2 antibodies revealed that while monoclonal antibodies generated in our laboratory were suitable for detection of endogenous TRPV2 by western blot, immunoprecipitation and immunocytochemistry, the commercially available polyclonal antibodies we tested were not able to recognize endogenous TRPV2. We used our newly generated and validated TRPV2 antibodies to determine the effects of insulin-like growth factor 1 (IGF-1) on TRPV2 surface expression in heterologous and endogenous expression systems. We found that IGF-1 had little to no effect on trafficking and plasma membrane expression of TRPV2. Overall, these new TRPV2 monoclonal antibodies served to dispel the controversy of the effects of IGF-1 on TRPV2 plasma membrane expression and will clarify the role TRPV2 plays in cellular function. Furthermore, our strategy of using full-length tetrameric TRP channels may allow for the generation of antibodies against other TRP channels of unclear function.
Insights
New monoclonal antibodies for Transient Receptor Potential Vanilloid 2 (TRPV2) were developed and validated. These tools show insulin-like growth factor 1 (IGF-1) does not affect TRPV2 surface expression, resolving prior scientific debate.
Area of Science:
- Molecular biology
- Cell biology
- Immunology
Background:
- Transient Receptor Potential Vanilloid 2 (TRPV2) is a calcium-permeable channel implicated in cellular processes.
- Previous studies on TRPV2 trafficking and function are hindered by a lack of validated antibodies.
- Conflicting results exist regarding growth factor signaling, like insulin-like growth factor 1 (IGF-1), and TRPV2 surface expression.
Purpose of the Study:
- To develop and characterize novel monoclonal antibodies for accurate detection of endogenous TRPV2.
- To investigate the effect of IGF-1 on TRPV2 trafficking and plasma membrane expression using validated antibodies.
Main Methods:
- Generation of monoclonal antibodies against full-length TRPV2.
- Validation of newly developed antibodies via Western blot, immunoprecipitation, and immunocytochemistry.
- Comparison of novel antibodies with commercially available polyclonal TRPV2 antibodies.
- Assessment of IGF-1 effects on TRPV2 surface expression in various cell systems.
Main Results:
- Newly generated monoclonal antibodies successfully detected endogenous TRPV2.
- Commercially available polyclonal TRPV2 antibodies failed to recognize endogenous TRPV2.
- IGF-1 demonstrated minimal to no impact on TRPV2 trafficking and plasma membrane expression.
Conclusions:
- Validated monoclonal antibodies are essential for reliable TRPV2 research.
- IGF-1 does not significantly alter TRPV2 surface expression, clarifying previous controversies.
- This antibody generation strategy can be applied to other TRP channels.

